Effect of gender and CYP2C9 and CYP2C8 polymorphisms on the pharmacokinetics of ibuprofen enantiomers

被引:25
作者
Ochoa, Dolores [1 ]
Prieto-Perez, Rocio [1 ]
Roman, Manuel [1 ]
Talegon, Maria [1 ]
Rivas, Angela [1 ]
Galicia, Ignacio [2 ]
Abad-Santos, Francisco [1 ,3 ]
Cabaleiro, Teresa [1 ,3 ]
机构
[1] Hosp Univ Princesa, Clin Pharmacol Serv, Inst Teofilo Hernando, Inst Invest Sanitaria Princesa IP, Madrid 28006, Spain
[2] Fdn Teofilo Hernando, Madrid 28049, Spain
[3] Inst Salud Carlos III, CIBERehd, Madrid 28029, Spain
关键词
CYP2C8; CYP2C9; ibuprofen; pharmacokinetics; polymorphisms; CYTOCHROME P4502C9 POLYMORPHISMS; IN-VITRO; FUNCTIONAL-CHARACTERIZATION; HEALTHY-VOLUNTEERS; METABOLISM; PHARMACODYNAMICS; GENOTYPES; ACID; (R)-IBUPROFEN; VARIABILITY;
D O I
10.2217/pgs.15.40
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aim: To evaluate the effect of polymorphisms in CYP2C9 and CYP2C8 and gender on the pharmacokinetics of the enantiomeric forms of ibuprofen. Materials & methods: 122 healthy volunteers were genotyped for polymorphisms in CY2C8 and CYP2C9 using real-time PCR. Results:CYP2C8 polymorphisms affected neither R- nor S-ibuprofen. CYP2C9*3 and CYP2C9*2 carriers had a lower S-ibuprofen clearance and a higher S-ibuprofen AUC and half-life. R-ibuprofen clearance was decreased in CYP2C9*3 carriers. Gender affected R-ibuprofen and S-ibuprofen pharmacokinetics. Multiple regression analysis showed that CYP2C9*2, CYP2C9*3 and gender were associated with S-ibuprofen clearance, but only CYP2C9*3 was associated with R-ibuprofen clearance. Conclusion: The pharmacokinetics of S-ibuprofen and R-ibuprofen is affected by CYP2C9 polymorphisms and gender. CYP2C8 polymorphisms do not have a significant role. Original submitted 6 February 2015; Revision submitted 1 April 2015
引用
收藏
页码:939 / 948
页数:10
相关论文
共 50 条
  • [21] CYP2C9 polymorphisms: Considerations in NSAID therapy
    Ali, Zaynah K.
    Kim, Rebekah J.
    Ysla, Francis M.
    CURRENT OPINION IN DRUG DISCOVERY & DEVELOPMENT, 2009, 12 (01) : 108 - 114
  • [22] Effect of SHR0302 on the pharmacokinetics of CYP3A4, CYP2C8, CYP2C9 and CYP2C19 probe substrates in healthy volunteers: A cocktail analysis
    Fu, Meng
    Luo, Lin
    Feng, Sheng
    Lin, Hongda
    Lu, Zekun
    Gu, Fei
    Fan, Yang
    Wu, Bing
    Huang, Jianying
    Shen, Kai
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 89 (12) : 3659 - 3668
  • [23] The CYP2C8 inhibitor gemfibrozil does not affect the pharmacokinetics of zafirlukast
    Karonen, Tiina
    Neuvonen, Pertti J.
    Backman, Janne T.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 67 (02) : 151 - 155
  • [24] Effects of CYP2C9 genetic polymorphisms on the pharmacokinetics of zafirlukast
    Hyun-Jee Lee
    Young-Hoon Kim
    Se-Hyung Kim
    Choong-Min Lee
    Ae-Yun Yang
    Choon-Gon Jang
    Seok-Yong Lee
    Jung-Woo Bae
    Chang-Ik Choi
    Archives of Pharmacal Research, 2016, 39 : 1013 - 1019
  • [25] Enzymatic activity of 38 CYP2C9 genotypes on ibuprofen
    Yuan, Ling-jing
    Li, Xiang-yu
    Ye, Feng
    Li, Xin-yue
    Li, Qing-qing
    Zhong, Yun-shan
    Wang, Shi-yu
    Wang, Ya-hui
    Hu, Guo-xin
    Cai, Jian-ping
    Li, Jun-wei
    FOOD AND CHEMICAL TOXICOLOGY, 2023, 178
  • [26] Frequency of CYP2C9 variant alleles, including CYP2C9*13 in a Korean population and effect on glimepiride pharmacokinetics
    Lee, H. W.
    Lim, M. -S.
    Lee, J.
    Jegal, M. -Y.
    Kim, D. -W.
    Lee, W. -K.
    Jang, I. -J.
    Shin, J. -G.
    Yoon, Y. -R.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2012, 37 (01) : 105 - 111
  • [27] Efficacy of piroxicam for postoperative pain after lower third molar surgery associated with CYP2C8*3 and CYP2C9
    Calvo, Adriana Maria
    Zupelari-Goncalves, Paulo
    Dionisio, Thiago Jose
    Brozoski, Daniel Thomas
    Faria, Flavio Augusto
    Santos, Carlos Ferreira
    JOURNAL OF PAIN RESEARCH, 2017, 10 : 1581 - 1589
  • [28] Evaluation of Concomitant Antiretrovirals and CYP2C9/CYP2C19 Polymorphisms on the Pharmacokinetics of Etravirine
    Green, Bruce
    Crauwels, Herta
    Kakuda, Thomas N.
    Vanveggel, Simon
    Brochot, Anne
    CLINICAL PHARMACOKINETICS, 2017, 56 (05) : 525 - 536
  • [29] Effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of gliclazide in healthy subjects
    Kang, Pureum
    Cho, Chang-Keun
    Jang, Choon-Gon
    Lee, Seok-Yong
    Lee, Yun Jeong
    Choi, Chang-Ik
    Bae, Jung-Woo
    ARCHIVES OF PHARMACAL RESEARCH, 2023, 46 (05) : 438 - 447
  • [30] The effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of glipizide in Chinese subjects
    Bo Tan
    Yi-Fan Zhang
    Xiao-Yan Chen
    Xiao-Hua Zhao
    Guo-Xin Li
    Da-Fang Zhong
    European Journal of Clinical Pharmacology, 2010, 66 : 145 - 151